Safety and Effectiveness of Letermovir in Allogenic Hematopoietic Stem Cell Transplantation Recipients: Interim Report of Post-marketing Surveillance in Japan
ConclusionsInterim data from this largest of real-world studies confirm the safety and effectiveness of letermovir for CMV prophylaxis in Japanese allo-HSCT recipients. Given the limited data on Asian patients for letermovir use, this survey will provide valuable information for medical decision-making in routine clinical practice, serving as a vital supplement to the results obtained from clinical trials.
Source: Clinical Drug Investigation - Category: Drugs & Pharmacology Source Type: research
More News: American Health | Clinical Trials | Cytomegalovirus | Drugs & Pharmacology | Japan Health | Stem Cell Therapy | Stem Cells | Study | Transplants | Trump | USA Health